1-20 of 24
Shen Yin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Adam Braun, Stephen J. Schuster, Loretta Nastoupil, Nancy L. Bartlett, Mazyar Shadman, Anita Kumar, Dimitrios Tzachanis, Dai Chihara, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 6555.
https://doi.org/10.1182/blood-2024-198409
Published: 2024
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett
Journal: Blood
Blood (2024) 144 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2024-197902
Published: 2024
Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Mazyar Shadman, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit E. Assouline, Laurie H. Sehn, John Kuruvilla, Pratyush Giri, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Connie Y. Ma, Samuel Tracy, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2024-197897
Published: 2024
Journal Articles

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Lihua E. Budde, Adam J. Olszewski, Bei Hu, Nikesh Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Kallemeijn, Victor Orellana-Noia, Lisa Musick, Natasha Shamas, Navdeep Pal, Ashwini Shewade, Jason R. Westin
Journal: Blood
Blood (2024) 144 (Supplement 1): 2373.
https://doi.org/10.1182/blood-2024-194340
Published: 2024
Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Clinical Trials & Observations
Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Stephen J. Schuster, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Derrick Kaufman, Antonia Kwan, Elicia Penuel, Christopher R. Bolen, Lihua Elizabeth Budde
Journal: Blood
Blood blood.2024025454.
https://doi.org/10.1182/blood.2024025454
Published: 2024
Includes: Supplemental data
Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Clinical Trials & Observations
Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Journal: Blood
Blood (2024) 143 (9): 822–832.
https://doi.org/10.1182/blood.2023022348
Published: 2024
Includes: Supplemental data
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 614.
https://doi.org/10.1182/blood-2023-173796
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 603.
https://doi.org/10.1182/blood-2023-173692
Published: 2023
Journal Articles

Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)

Brendan C Bender, Chi-Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael C. Wei, Pascal Chanu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2810.
https://doi.org/10.1182/blood-2023-182086
Published: 2023
Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster
Journal: Blood
Blood (2023) 142 (Supplement 1): 1752.
https://doi.org/10.1182/blood-2023-190201
Published: 2023
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 3771–3772.
https://doi.org/10.1182/blood-2022-157710
Published: 2022
Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel
Journal: Blood
Blood (2022) 140 (Supplement 1): 6448–6449.
https://doi.org/10.1182/blood-2022-157934
Published: 2022
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 1467–1470.
https://doi.org/10.1182/blood-2022-157691
Published: 2022
Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Nancy L. Bartlett, Pratyush Giri, L. Elizabeth Budde, Stephen J. Schuster, Sarit Assouline, Matthew J. Matasar, Sung-Soo Yoon, Miguel Canales, Norma C. Gutierrez, Keith Fay, Chan-Yoon Cheah, Paula Marlton, Volker Wiebking, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Mingzhu Zhou, Elicia Penuel, Carol O'Hear, Laurie H. Sehn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3573.
https://doi.org/10.1182/blood-2021-147937
Published: 2021
Journal Articles

Efficacy and Safety of Extended Use of Romiplostim Treatment for Chemotherapy-Induced Thrombocytopenia

Cy R Wilkins, Jocelyn Ortiz, Leah Gilbert, Shen Yin, Jodi V. Mones, Rekha Parameswaran, Simon Mantha, Gerald A. Soff
Journal: Blood
Blood (2021) 138 (Supplement 1): 2075.
https://doi.org/10.1182/blood-2021-145958
Published: 2021
Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Elizabeth Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Michelle Y. Doral, Chi-Chung Li, Huang Huang, Raluca Negricea, Elicia Penuel, Carol O'Hear, Nancy L. Bartlett
Journal: Blood
Blood (2021) 138 (Supplement 1): 127.
https://doi.org/10.1182/blood-2021-145872
Published: 2021
Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J Matasar, MD, Chan Yoon Cheah, MBBS, Dok Hyun Yoon, Sarit E Assouline, MD MSc, Nancy L. Bartlett, MD, Matthew Ku, Pratyush Giri, Anna Johnston, MBBS (Hons 1), FRACP, FRCPA, Ian W. Flinn, MD PhD, Andre H. Goy, MD, Dimitrios Tzachanis, MD PhD, Carol O'Hear, Shen Yin, Iris To, Kati Sarouei, Chi-Chung Li, Brendan C. Bender, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135818
Published: 2020
Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Sarit E Assouline, MD MSc, Won Seog Kim, MD PhD, Laurie H. Sehn, MDMPH, Stephen J. Schuster, MD, Chan Yoon Cheah, MBBS, Loretta J. Nastoupil, MD, Mazyar Shadman, Sung-Soo Yoon, MD PhD, Matthew J Matasar, MD, Catherine Diefenbach, MD, Gareth P. Gregory, Nancy L. Bartlett, MD, Michael C. Wei, Michelle Y. Doral, Shen Yin, Raluca Negricea, Chi-Chung Li, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-135839
Published: 2020
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019